(-0.03%) 5 306.74 points
(0.02%) 39 918 points
(-0.07%) 16 731 points
(0.88%) $79.32
(3.10%) $2.49
(-0.41%) $2 385.00
(0.46%) $29.87
(-0.13%) $1 068.70
(0.17%) $0.920
(0.32%) $10.70
(0.11%) $0.789
(0.16%) $90.83
@ $3.64
Issued: 13 Feb 2024 @ 15:55
Return: -9.22%
Previous signal: Feb 9 - 13:51
Previous signal:
Return: -3.84 %
Live Chart Being Loaded With Signals
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders...
Stats | |
---|---|
Today's Volume | 839 789 |
Average Volume | 381 126 |
Market Cap | 191.22M |
EPS | $0 ( 2024-05-15 ) |
Next earnings date | ( $-0.580 ) 2024-08-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.180 |
ATR14 | $0.00900 (0.27%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-25 | Demopulos Gregory A Md | Buy | 725 000 | Stock Option (right to buy) |
2024-04-25 | Jacobsen Michael A | Buy | 100 000 | Stock Option (right to buy) |
2024-04-25 | Cancelmo Peter B | Buy | 100 000 | Stock Option (right to buy) |
2023-11-17 | Demopulos Gregory A Md | Buy | 15 000 | Common Stock |
2023-11-15 | Demopulos Peter A Md | Buy | 10 000 | Common Stock |
INSIDER POWER |
---|
98.88 |
Last 99 transactions |
Buy: 4 085 039 | Sell: 554 578 |
Volume Correlation
Omeros Corp Correlation
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Omeros Corp Correlation - Currency/Commodity
Omeros Corp Financials
Annual | 2023 |
Revenue: | $0 |
Gross Profit: | $-920 000 (0.00 %) |
EPS: | $-1.880 |
FY | 2023 |
Revenue: | $0 |
Gross Profit: | $-920 000 (0.00 %) |
EPS: | $-1.880 |
FY | 2022 |
Revenue: | $0 |
Gross Profit: | $-952 000 (0.00 %) |
EPS: | $0.460 |
FY | 2021 |
Revenue: | $0.00 |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $3.12 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Omeros Corp
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators